Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

被引：0

作者：

van Meerten, Tom ^{[1
]}

Kersten, M. J. ^{[2
]}

Lacoboni, Gloria ^{[3
]}

Hess, Georg ^{[4
]}

Mutsaers, Pim ^{[5
]}

Garcia-Sancho, Alejandro Martin ^{[6
]}

Goy, Andre ^{[7
]}

Gine, Eva ^{[8
]}

Hill, Brian T. ^{[9
]}

Weng, Wen-Kai ^{[10
]}

Dreyling, Martin ^{[11
]}

Reagan, Patrick M. ^{[12
]}

Patel, Krish ^{[13
]}

Galal, Ahmed ^{[14
]}

Herbaux, Charles ^{[15
]}

Sanderson, Robin ^{[16
]}

Zheng, Dan ^{[17
]}

Kanska, Justyna ^{[17
]}

Zhang, Wangshu ^{[17
]}

Khalid, Rita Damico ^{[17
]}

Kloos, Loana ^{[17
]}

Wang, Michael ^{[18
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

[2] Locat Univ Amsterdam, Canc Ctr Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

[3] Vall dHebron Univ Hosp, Barcelona, Spain

[4] Johannes Gutenberg Univ Mainz, Mainz, Germany

[5] Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[6] Salamanca Univ Hosp, Hematol Dept, IBSAL, CIBERONC, Salamanca, Spain

[7] John Theurer Canc Ctr, Hackensack, NJ USA

[8] Hosp Clin Barcelona, IDIBAPS, CIBERONC, Barcelona, Spain

[9] Cleveland Clin Fdn, Cleveland, OH USA

[10] Stanford Univ, Div Blood & Marrow Transplantat & Cellular Therapy, Sch Med, Palo Alto, CA USA

[11] Ludwig Maximilian Univ Hosp, Dept Med 3, Munich, Germany

[12] Univ Rochester, Med Ctr, Rochester, NY USA

[13] Swedish Canc Inst, Seattle, WA USA

[14] Carol G Simon Canc Ctr, Morristown, NJ USA

[15] CHU Montpellier, Hematol Clin, Montpellier, France

[16] Kings Coll Hosp London, London, England

[17] Kite Gilead Co, Santa Monica, CA USA

[18] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-198021

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：748 / 750

页数：3

共 36 条

[31] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL): Results from Phase 2 of ZUMA-2
Wang, Michael
Munoz, Javier
Goy, Andre
Locke, Frederick
Jacobson, Caron
Hill, Brian
Timmerman, John
Holmes, Houston
Jaglowski, Samantha
Flinn, Ian
McSweeney, Peter
Miklos, David
Pagel, John
Kersten, Marie Jose
Peng, Weimin
Zheng, Lianqing
Rossi, John
Jain, Rajul
Rao, Arati
Reagan, Patrick
BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 41 - 43
[32] ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Wang, M.
Locke, F. L.
Siddiqi, T.
Castro, J.
Shah, B.
Lee, H.
Budde, L. E.
Choi, M.
Anasetti, C.
Champlin, R.
Forman, S.
Kipps, T.
Bot, A.
Rossi, J. M.
Navale, L.
Jiang, Y.
Aycock, J.
Elias, M.
Wiezorek, J.
Go, W. Y.
ANNALS OF ONCOLOGY, 2016, 27
[33] Primary Analysis of ZUMA7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) versus StandardofCare (SOC) Therapy in Patients (Pts) with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Ghobadi, Armin
Locke, Frederick L.
Miklos, David B.
Jacobson, Caron A.
Perales, Miguel-Angel
Kersten, Marie Jose
Oluwole, Olalekan O.
Rapoport, Aaron P.
McGuirk, Joseph P.
Pagel, John M.
Munoz, Javier
Farooq, Umar
van Meerten, Tom
Reagan, Patrick M.
Sureda, Anna
Flinn, Ian W.
Vandenberghe, Peter
Song, Kevin W.
Dickinson, Michael
Minnema, Monique C.
Riedell, Peter A.
Leslie, Lori A.
Chaganti, Sridhar
Yang, Yin
Filosto, Simone
Schupp, Marco
To, Christina
Cheng, Paul
Gordon, Leo I.
Westin, Jason R.
MOLECULAR THERAPY, 2022, 30 (04) : 519 - 519
[34] Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Chaganti, Sridhar
Cwynarski, Kate
Cunningham, David
Locke, Frederick L.
Miklos, David B.
Jacobson, Caron A.
Perales, Miguel-Angel
Kersten, Marie Jose
Oluwole, Olalekan O.
Ghobadi, Armin
Rapoport, Aaron P.
McGuirk, Joseph P.
Pagel, John M.
Munoz, Javier
Farooq, Umar
van Meerten, Tom
Reagan, Patrick M.
Sureda, Anna
Flinn, Ian W.
Vandenberghe, Peter
Song, Kevin W.
Dickinson, Michael
Minnema, Monique C.
Riedell, Peter A.
Leslie, Lori A.
Yang, Yin
Filosto, Simone
Schupp, Marco
To, Christina
Cheng, Paul
Gordon, Leo I.
Radford, John
Westin, Jason R.
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 20 - 22
[35] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Oluwole, Olalekan O.
Forcade, Edouard
Munoz, Javier
de Guibert, Sophie
Vose, Julie M.
Bartlett, Nancy L.
Lin, Yi
Deol, Abhinav
McSweeney, Peter A.
Goy, Andre H.
Kersten, Marie Jose
Jacobson, Caron A.
Farooq, Umar
Minnema, Monique C.
Thieblemont, Catherine
Timmerman, John
Stiff, Patrick
Avivi, Irit
Tzachanis, Dimitrios
Zheng, Yan
Vardhanabhuti, Saran
Nater, Jenny
Shen, Rhine R.
Miao, Harry
Kim, Jenny
van Meerten, Tom
BLOOD, 2022, 140 : 10399 - 10401
[36] Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3-ITD-mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment.
Levis, Mark J.
Smith, Catherine Choy
Ishizuka, Koji
Kobayashi, Ken
Arunachalam, Meena
Wang, Yibin
Lazzaretto, Deborah
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 →